Peyronie's disease: Etiology, epidemiology and medical treatment

Urologic Clinics of North America

Volumn 32, Issue 4, 2005, Pages 469-478

  Greenfield, Jason M ^a   Levine, Laurence A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; CARNITINE; COLCHICINE; COLLAGENASE; CORTISONE; DEXAMETHASONE; HYDROCORTISONE; IBUPROFEN; INTERFERON; LIDOCAINE; STEROID; TAMOXIFEN; TAMOXIFEN CITRATE; TRIAMCINOLONE; VERAPAMIL;

ATROPHY; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG FEVER; ERYTHEMA; EXTRACORPOREAL LITHOTRIPSY; HUMAN; IONTOPHORESIS; MYALGIA; PATHOGENESIS; PEYRONIE DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

HUMANS; MALE; PENILE INDURATION;

EID: 27744537926     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2005.08.011     Document Type: Review

References (75)

1. L.J.T. Murphy Miscellanea: Peyronie's disease (fibrous cavernositis) The history of urology 1st ed. 1972 Charles C. Thomas Springfield (IL) 485 486
2. M.B. Wesson Peyronie's disease (plastic induration) cause and treatment J Urol 49 1943 350 356
3. Hunter J. Of the treatment of occasional symptoms of the gonorrhea. In: Nicol G, Johnson J, editors. A treatise on the venereal disease. 2nd ed. Philadelphia: J. Webster, 1818. p. 88-9.
4. J. Abernethy The consequences of gonorrhea. Lecture on anatomy, surgery, and pathology: including observations on the nature and treatment of local diseases, delivered at St. Bartholomew's and Christ's Hospitals 1st ed. 1828 James Balcock London (England) p. 205
5. L.A. Levine Treatment of Peyronie's disease with intralesional verapamil injection J Urol 158 4 1997 1395 1399
6. C.J. Devine Jr., K.D. Somers, and S.G. Jordan Proposal: trauma as the cause of the Peyronie's lesion J Urol 157 1 1997 285 290
7. J. Zargooshi Trauma as the cause of Peyronie's disease: penile fracture as a model of trauma J Urol 172 1 2004 186 188
8. T.R. Magee, A. Qian, and J. Rajfer Gene expression profiles in the peyronie's disease plaque Urology 59 3 2002 451 457
9. A. Qian, R.A. Meals, and J. Rajfer Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture Urology 64 2 2004 399 404
10. Cole A. Increased endogenous inhibitors of collagenases within Peyronie's plaques may represent a scar remodeling disorder [Abstr 944]. Annual Meeting of the American Urological Association; San Antonio, TX. May 21-26, 2005.
11. Davila HH, Ferrini MG, Rajfer J, et al. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int 91(9):830-8.
12. Haag SM, Hauck EW, Altinkilic B, et al. Alterations in the transforming-growth-factor-beta pathway as a possible risk factor in the pathogenesis of Peyronie's disease [Abstr 939]. Annual Meeting of the American Urological Association; San Antonio, TX. May 21-26, 2005.
13. Davila HH, Magee TR, Zuniga F, et al. Plasminogen activator inhibitor-1 (PAI-1) is increased in human Peyronie's disease [Abstr 943]. Annual Meeting of the American Urological Association; San Antonio, TX. May 21-26, 2005.
14. H.J. Polkey ID induratio penis plastica Urol Cut Rev 32 1928 287 308
15. W. Ludvik, and K. Wasserburger Die Radiumbehandlung der induratio penis plastica Z Urol Nephrol 61 1968 319 325
16. C.J. Devine Introduction to Peyronie's disease J Urol 157 1997 272 275
17. La Rochelle JC, Levine LA. Survey of primary care physisicans and urologists regarding Peyronie's disease. [Abstr 941]. Annual Meeting of the American Urological Association; San Antonio, TX. May 21-26, 2005.
18. M.B. Lindsay, D.M. Schain, and P. Grambsch The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984 J Urol 146 4 1991 1007 1009
19. F. Sommer, U. Schwarzer, and G. Wassmer Epidemiology of Peyronie's disease Int J Impot Res 14 5 2002 379 383
20. J.P. Mulhall, S.D. Creech, and S.A. Boorjian Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening J Urol 171 6 Pt 1 2004 2350 2353
21. M.K. Gelbard, F. Dorey, and K. James The natural history of Peyronie's disease J Urol 144 6 1990 1376 1379
22. A. Kadioglu, A. Tefekli, and H. Erol A retrospective review of 307 men with Peyronie's disease J Urol 168 3 2002 1075 1079
23. Mulhall JP, Guhring P, Depierro C. Intralesional verapamil prevents progression of Peyronie's disease [Abstr 936]. Annual Meeting of the American Urological Association; San Antonio, TX. May 21-26, 2005.
24. L.A. Levine, C.R. Estrada, and D.W. Storm Peyronie's disease in younger men: Characteristics and treatment results J Androl 24 1 2003 27 32
25. A. Tefekli, E. Kandirali, and H. Erol Peyronie's disease in men under 40: characteristics and outcome Int J Impot Res 13 1 2001 18 23
26. A. Briganti Clinical presentation of Peyronie's disease in young patients Int J Impot Res 15 Suppl 6 2003 S44 S47
27. J.L. Williams, and G.G. Thomas The natural history of Peyronie's disease J Urol 103 1 1970 75 76
28. A. Kadioglu, A. Tefekli, and O. Sanly Lessons learned from 307 men with Peyronie's disease J Urol 165 5 Suppl 2001 202 203 [Abstract 838]
29. W.W. Scott, and P.L. Scardino A new concept in the treatment of Peyronie's disease South Med J 41 1948 173 177
30. E. Akkus, S. Carrier, and J. Rehman Is colchicine effective in Peyronie's disease? A pilot study Urology 44 2 1994 291 295
31. A. Kadioglu, A. Tefekli, and T. Koksal Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome Int J Impot Res 12 3 2000 169 175
32. C.J. Zarafonetis, and T.M. Horrax Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba) J Urol 81 6 1959 770 772
33. R. Hasche-Klunder Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTOBA) (author's transl) Urologe A 17 4 1978 224 227
34. * (aminobenzoate potassium) J Urol 6 4 Suppl 1999 205 [Abstr 785]
35. D.J. Ralph, M.D. Brooks, and G.F. Bottazzo The treatment of Peyronie's disease with tamoxifen Br J Urol 70 6 1992 648 651
36. A.A. Colletta, L.M. Wakefield, and F.V. Howell Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts Br J Cancer 62 3 1990 405 409
37. C. Teloken, E.L. Rhoden, and T.M. Grazziotin Tamoxifen versus placebo in the treatment of Peyronie's disease J Urol 162 6 1999 2003 2005
38. G. Biagiotti, and G. Cavallini Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report BJU Int 88 1 2001 63 67
39. R.B. Kelly Pathways of protein secretion in eukaryotes Science 230 4721 1985 25 32
40. J. Aggeler, S.M. Frisch, and Z. Werb Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts J Cell Biol 98 5 1984 1662 1671
41. R.C. Lee, and J.A. Ping Calcium antagonists retard extracellular matrix production in connective tissue equivalent J Surg Res 49 5 1990 463 466
42. D.J. Martin, K. Badwan, and M. Parker Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea J Urol 168 6 2002 2483 2485
43. G.H. Teasley Peyronie's disease a new approach J Urol 71 5 1954 611 614
44. H. Bodner, A.H. Howard, and J.H. Kaplan Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy J Urol 72 1954 400 431
45. C.C. Winter, and R. Khanna Peyronie's disease: results with dermo-jet injection of dexamethasone J Urol 14 1975 898 900
46. G. Williams, and N.A. Green The non-surgical treatment of Peyronie's disease Br J Urol 52 1980 392 395
47. M.K. Gelbard, R. Walsh, and J.J. Kaufman Collagenase for Peyronie's disease: experimental studies Urol Res 10 1982 135 140
48. M.K. Gelbard, A. Lindner, and J.J. Kaufman The use of collagenase in the treatment of Peyronie's disease J Urol 134 1985 280 283
49. M.K. Gelbard, K. James, and P. Riach Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study J Urol 149 1 1993 56 58
50. L.A. Levine, P.F. Merrick, and R.C. Lee Intralesional verapamil injection for the treatment of Peyronie's disease J Urol 151 6 1994 1522 1524
51. J. Rehman, A. Benet, and A. Melman Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study Urology 51 4 1998 620 626
52. L.A. Levine, K.E. Goldman, and J.M. Greenfield Experience with intraplaque injection of verapamil for Peyronie's disease J Urol 168 2 2002 621 625
53. M.R. Duncan, B. Berman, and U.O. Nseyo Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma Scand J Urol Nephrol 25 2 1991 89 94
54. H.E. Wegner, R. Andresen, and H.H. Knispel Treatment of Peyronie's disease with local interferon-alpha 2b Eur Urol 28 3 1995 236 240
55. H.E. Wegner, R. Andresen, and H.H. Knispel Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease Eur Urol 32 2 1997 190 193
56. I.S. Judge, and Z.S. Wisniewski Intralesional interferon in the treatment of Peyronie's disease: a pilot study Br J Urol 79 1 1997 40 42
57. S. Ahuja, T.J. Bivalacqua, and J. Case A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease J Androl 20 4 1999 444 448
58. G. Dang, R. Matern, and T.J. Bivalacqua Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease South Med J 97 1 2004 42 46
59. W. Hellstrom, C. Eichelberg, and J.L. Pryor A single-blind, multi-center, placebo-controlled study to assess the safety and efficacy of intralesional interferon alpha-2b in the non-surgical treatment of Peyronie's disease J Urol 169 4 Suppl 2003 274 [Abstr 1065]
60. L.A. Levine Review of current nonsurgical management of Peyronie's disease Int J Impot Res 15 Suppl 5 2003 S113 S120
61. R. Manikandan, W. Islam, and V. Srinivasan Evaluation of extracorporeal shock wave therapy in Peyronie's disease Urology 60 5 2002 795 799
62. T. Lebret, G. Loison, and J.M. Herve Extracorporeal shock wave therapy in the treatment of Peyronie's disease: experience with standard lithotriptor (siemens-multiline) Urology 59 5 2002 657 661
63. E.W. Hauck, B.M. Altinkilic, and M. Ludwig Extracorporeal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach Eur Urol 38 6 2000 663 669
64. C.R. Riedl, E. Plas, and P. Engelhardt Iontophoresis for treatment of Peyronie's disease J Urol 163 1 2000 95 99
65. F. Montorsi, A. Salonia, and G. Guazzoni Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results J Androl 21 1 2000 85 90
66. S.M. Di Stasi, A. Giannantoni, and G. Capelli Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease BJU Int 91 9 2003 825 829
67. S.M. Di Stasi, A. Giannantoni, and R.L. Stephen A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease J Urol 171 4 2004 1605 1608
68. L.A. Levine, C.R. Estrada, and W. Shou Tunica albuginea tissue analysis after electromotive drug administration J Urol 169 5 2003 1775 1778
69. L.A. Levine, and V.L. Sevier A double-blind, placebo-controlled trial of electromotive drug administration (EMDA) using verapamil vs. saline for Peyronie's disease: preliminary results J Urol 169 4 Suppl 2003 274 275 [Abstr 1066]
70. J.C. Ojingwa, and R.R. Isseroff Electrical stimulation of wound healing J Invest Dermatol 121 1 2003 1 12
71. R.M. Prieto Castro, M.E. Leva Vallejo, and J.C. Regueiro Lopez Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease BJU Int 91 6 2003 522 524
72. V. Mirone, A. Palmieri, and A.M. Granata Ultrasound-guided ESWT in Peyronie's disease plaques Arch Ital Urol Androl 72 4 2000 384 387
73. V. Mirone, C. Imbimbo, and A. Palmieri Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica Eur Urol 36 4 1999 327 330
74. G. Cavallini, G. Biagiotti, and A. Koverech Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease BJU Int 89 9 2002 895 900
75. L.A. Levine, and J.M. Greenfield Establishing a standardized evaluation of the man with Peyronie's disease Int J Impot Res 15 Suppl 5 2003 S103 S112